pazopanib and Diabetic-Retinopathy

To determine the efficacy of pazopanib eye drops in the streptozotocin induced diabetic retinopathy rat model.. A 0.5% w/v pazopanib suspension was prepared in phosphate buffered saline (PBS, pH 7.4) in the presence of 0.5% w/v sodium carboxymethyl cellulose. Brown Norway rats were divided into three groups (n=4) - (1) healthy, (2) diabetic, and (3) diabetic with treatment. The drug suspension was administered twice daily as eye drops to group 3 for 30 days. Efficacy parameters including the number of adherent leukocytes in the retinal vasculature (leukostasis), blood-retinal FITC-dextran leakage, and vitreous-to-plasma protein ratio were measured.. Pazopanib suspension in the form of eye drops significantly reduced leukostasis (32%), FITC-dextran leakage (39%), and the vitreous-to-plasma protein ratio (64%) in diabetic animals compared to untreated diabetic group.. Pazopanib eye drops can alleviate retinal complications of diabetic retinopathy.

Topics: Administration, Ophthalmic; Animals; Blood Glucose; Blood Proteins; Blood-Retinal Barrier; Body Weight; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Indazoles; Leukocytes; Leukostasis; Macular Edema; Male; Molecular Targeted Therapy; Ophthalmic Solutions; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Inbred BN; Sulfonamides; Time Factors; Vitreous Body